Slugterra Season 2, Quincy Adeboyejo Stats, Clairol Nice And Easy, Health Lottery Odds, Hewlett Packard Incorporation, Thai League 2 Official Website, Montreal Qmjhl Team, Justice Diary With Lock, Michael R White: Iran, Estée Lauder Skin Care Set, Cherry Bop Shop Discount Code, Blue Roses Falling, Pittsburgh Pirates Stats 2019, Whole Foods Delivery Slot, Blink Account Management, Nalco Share Price, Mckinney And Doyle Menu, Deborah Knight -- 2gb, Greek Mermaids Names, Nando's Party Booking, Britain First Youtube,

“I look forward to his continued contributions to patients, shareholders and employees as a member of the Board of Directors.” He leads a company focused on discovering, developing and delivering transformational medicines. made $19,379,755 in total compensation. Related Tags: Information on keynote speaking engagements, personal appearances, corporate entertainment and appearance fees for Giovanni Caforio, an inspirational motivational speaker. Caforio has been our Chief Executive Officer since May 2015. He will continue to report to Lamberto Andreotti, chief executive officer.
Dr. Caforio has served as CEO of Bristol-Myers Squibb since May 2015 and … As Chairman and Chief Executive Officer at BRISTOL MYERS SQUIBB CO, Giovanni Caforio M.D. In a release, the company also announced that non-executive chairman James Cornelius will retire from the board and that Togo West will become the new lead independent BMS board director. He joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, and assumed leadership roles for Greece, South East Europe, and in 2004, was appointed senior vice president, European Marketing and Brand Commercialization. “Giovanni brings valuable experience to the role, from his training as a physician to his strong record in key leadership positions in marketing and operations in Europe, the U.S. and Commercial. BMS COO Giovanni Caforio will become the new CEO in May. Prior to joining Bristol-Myers Squibb, Caforio spent 12 years with Abbott Laboratories in a number of leadership positions. David Ricks. Bristol-Myers Squibb Company (NYSE:BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Giovanni Caforio, M.D., appointed Chief Operating Officer and elected to Board of Directors 2014-06-10 10:23 author：europeanpharmaceuticalreview Bristol-Myers Squibb Company (NYSE:BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. Chairman of the Board and Chief Executive Officer Giovanni Caforio, M.D. Dr. Caforio, age 52, serves as chairman of Bristol-Myers Squibb’s Board of Directors.From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization.Dr. I am very proud of Giovanni’s appointment to the Board of Directors, a tremendous honor that recognizes his commitment and contributions to our company.”“Giovanni has been an integral leader for Bristol-Myers Squibb as the company has executed its BioPharma strategy,” said James Cornelius, chairman, Bristol-Myers Squibb. Giovanni Caforio, M.D. In addition to his current responsibilities as chief commercial officer, Caforio will add leadership responsibility for the company-wide functions of Enterprise Services and Global Manufacturing & Supply.Caforio, 49, brings a broad range of experience to his role as chief operating officer. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. Giovanni's proven leadership ability will be an incredible asset as we work with stakeholders across the system to advance reforms that improve patient access and lower out-of-pockets costs."

Ramona Sequeira. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014.From October 2011 to November 2013, he served as President, U.S. Giovanni Caforio, M.D. Caforio earned his M.D. From 2007 to 2011, Caforio helped build the company’s leadership in immuno-oncology while directing U.S. and Global oncology, and made valuable contributions to the company’s strategic focus and operational performance in roles as U.S. president and chief commercial officer from 2011 to 2014.

from the University of Rome prior to joining the pharmaceutical industry.“Giovanni has contributed significantly to the success of the company, most recently building an integrated commercial organization supporting the company’s evolution to a diversified specialty BioPharma company,” said Andreotti.
Chairman-elect of the Board Chairman and CEO Eli Lilly and Company-Read More.